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BACKGROUND: Diffuse panbronchiolitis is a clinical pathologic condition characterized by chronic inflammation
of respiratory bronchioles, with clinical features that position it as a differential diagnosis among the sinopulmonary
syndromes.
METHODS AND RESULTS: We present 4 cases (1 Black, 2 Japanese descendants, and 1 Japanese), living in Brazil,
in which the diagnosis was made by the clinical and radiological features and confirmed by transbronchial biopsy. The
clinical findings included chronic sinusitis, productive cough, rhonchi, and wheezes. The pulmonary function tests showed
an obstructive pattern. High resolution computerized tomography showed a diffuse nodular pattern, airway ectasia, and
airway wall thickening. The biopsy showed interstitial accumulation of foam cells and lymphoid cells in the walls of
respiratory bronchioles: 2 of our cases had bronchus-associated lymphoid tissue hyperplasia. We searched for the HLA Bw54
in all of our patients, but only 1 was positive. A low dose macrolide treatment was introduced, resulting in with clinical and
functional improvement. A score that rated the extent of nodules, airway ectasia, mucus plugging, and airway wall thickening
was applied on pre- and post-treatment High resolution computerized tomography results, revealing an improvement in
tomographic pattern related to that observed in the pulmonary function tests.
CONCLUSION: We conclude that diffuse panbronchiolitis is a systemic disease that is not exclusive to the Asian
population, whose clinical and radiological features should be better known by occidental pulmonary physicians.
DESCRIPTORS: Diffuse Panbronchiolitis. Bronchiolitis. Sinopulmonary syndromes. Interstitial lung disease.
Bronchiolectasis.
INTRODUCTION
Diffuse panbronchiolitis (DPB) is a
clinical pathologic condition charac-
terized by chronic inflammation of res-
piratory bronchioles; it was first de-
scribed in 1969 by Yamanaka et al.1.
In 1983, a large number of cases were
reported, and the clinical features and
diagnostic criteria were summarized2,
introducing DPB as a differential di-
agnosis among the sinopulmonary
syndromes. Although, this disease has
primarily been observed in Japan, case
reports around the world (in South
America3, North America4,5, and Eu-
rope6) have been described. In these
cases, the disease has occurred in pa-
tients either with or without a travel
history to the Far East. The paucity of
cases outside Japan, in Asian or non-
Asian patients, may reflect a genetic/
environmental factor or a misdiagnosis
of the disease. In this study, the clini-
cal, radiologic, and pathologic features
of 4 cases in people living in Brazil:
1 Black, 1 Japanese, and 2 of Japanese
descent.
METHODS
We describe 4 cases presented at our
division between 1995 and 1998. To
reach the diagnosis of DPB, we used the
following diagnostic criteria2,7: a) symp-
toms of chronic cough, sputum, and
dyspnea on exertion; b) physical signs
of rales and rhonchi; c) chest radiograph
showing diffusely disseminated fine
nodular shadows, mainly in the lower
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lung fields with hyperinflation; d) the
presence of at least 3 of the following
findings in a pulmonary function test:
the ratio between forced expiratory vol-
ume in 1 second and forced vital capac-
ity (FEV1/FVC) < 70% (absolute ratio);
FVC < 80% (predicted value); residual
volume > 150% (predicted value); or
PO2 <80 mmHg. The summary of the
clinical findings for our patients and of
the pulmonary function tests can be
seen in tables 1 and 2.
We also searched for the presence
of HLA Bw54, rheumatoid factor, and
antinuclear antibodies, and we meas-
ured the cold-agglutinin titer as the
level of immunoglobulin. Sputum
specimens from the 4 patients were
taken to determine the infection/colo-
nization of the airways. The laboratory
findings are described in table 3.
Chest radiographs and high resolu-
tion computed tomography (HRCT)
were taken. The radiological findings
are summarized in table 4. We used
HRCT as a method of treatment follow
up, utilizing a score that evaluated the
extent of nodular lesions, airway ecta-
sia, and mucus plugging, and the de-
gree of airway ectasia and airway wall
thickening8. The results of this score
can also be seen in table 4.
Our 4 patients underwent trans-
bronchial biopsy. The histological pat-
tern used as a diagnostic criterion9 was
the following: diffuse chronic airway
inflammation, with the predominant
site of the chronic inflammation being
the wall of membranous or respiratory
bronchioles and the centrilobular re-
gions, interstitial accumulation of foam
cells, and lymphoid cells in the wall of
respiratory bronchioles and adjacent al-
veolar ducts and alveoli (described as
the DPB unit lesion). Bronchus-associ-
ated lymphoid tissue (BALT) hyperpla-
sia was also described as a usual find-
ing in DPB10.
Table 1 - Clinical Features.
Case Age/Sex Race Cough Sputum Dyspnea Chronic Sinusitis Smoking History Wheezes Crackles
(years of symptoms) (packs/year) Rhonchi
1 58/Male Asian + + + 25 25 + +
(quit 6 yr ago)
2 63/Male Asian + + + 18 10 + +
(quit 36 yr ago)
3 70/Male Asian + + + 8 21 + +
(quit 40 yr ago)
4 43/Male Black + + + 18 no tobacco + +
history
+ present
Table 2 - Parameters of pulmonary function before and after 6 months of low dose macrolide treatment.
Case FVC FEV1 FEV1/FVC (%) FEF 25-75 Dlco (%) SatO2 at room air breathing (%)
(predicted value %)
1 Before 2.06 1.41 68 22 61 90
(53 %) (49 %)
After 2.23 1.40 63 40 75 91
(57 %) (48 %)
2 Before 1.58 0.78 50 25 37 71
(75 %) (46%)
After 2.23 1.26 57 24 76 90
(107 %) (74 %)
3 Before 3.03 1.55 51 20 Not 86
(88 %) (57 %) determined
After 3.26 2.09 64 37 96 91
(95 %) (77 %)
4 Before 1.89 0.93 59 13 61 90
(60 %) (35 %)
After 1.97 1.10 66 21 59 94
(63 %) (41 %)
FVC = Forced Inspiratory Capacity
FEV1 = Forced Expiratory Volume at 1st second
FEF25~75 = Forced Expiratory Flow at middle FVC
DLco = Carbon Monoxide Diffusing Capacity
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Our 4 patients fulfilled this
pathologic criterion, including the
presence of BALT hyperplasia seen in
patients 2 and 3. A sample of the his-
topathologic findings can be seen in
figure 1.
CASE 1
A 58-year-old male, born in Japan,
and living in Brazil for 30 years, and
traveling to Japan annually for the last
10 years. He had a 25 pack/year his-
tory of tobacco use but had discontin-
ued 6 years ago. He had experienced
chronic sinusitis since the age of 33.
About 15 years ago, he started experi-
encing dyspnea, dry cough, and
wheezing in episodes that lasted about
3 to 4 days. Since 1993, the cough had
been productive, and he had a wors-
ening of the dyspnea and wheezing.
Table 3 - Laboratory Results.
Case HLA Bw54 Cold-Agglutinin titer ANA RF Immunoglobulin Sputum Culture
1 Negative negative 1:40 258 IgG = 1620 mg/dl Pseudomonas
aeruginosa
2 Positive negative negative negative IgA = 415 mg/dl Stenotrophomonas
maltophilia
3 Negative negative 1:40 negative IgG = 1680 mg/dl Pseudomonas sp
4 Negative negative negative negative IgG = 1640 mg/dl Staphylococcus aureus
ANA = antinuclear antibodies
RF = rheumatoid factor
Table 4 - Radiograph Findings.
Case Chest X-ray HRCT CT Score
(pre/post-treatment)
1 Bilateral nodular infiltrate Large, medium and small 12 / 12
Airway wall thickening size bronchi wall thickening
Bronchiectasis Diffuse bronchiolectasis
2 Bilateral nodular infiltrate Small airway wall thickening 10 / 07
Airway wall thickening Mild bronchiolectasis
Hyperinflation
3 Bilateral reticulonodular infiltrate Small airway wall thickening 13 / 05
Hyperinflation Mild bronchiolectasis
4 Bilateral reticulonodular infiltrate Medium and small airway wall thickening 11 / 07
Hyperinflation Mild bronchiolectasis
 HRCT = High Resolution Computed Tomography
Figure 1 - Histopathologic picture of transbronchial biopsy of patient 1 showing branched
lymphocytes and foam cells interstitial accumulation (large arrow); BALT hyperplasia (small
arrow). (hematoxylin and eosin x 100).
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Physical examination revealed diffuse
expiratory wheezes and inspiratory
crackles mainly in the basal portions
of the lungs. Sinus films revealed bi-
lateral maxillary disease. The chest ra-
diograph and HRCT are described in
Table 4. Pulmonary function tests
showed a marked flow limitation. The
patient started a low-dose erythromy-
cin treatment that resulted in clinical
improvement.
CASE 2
A 63-year-old male, born in Brazil;
Japanese parents. He had a 10 pack/
year history of tobacco use but
stopped 36 years ago. He had no his-
tory of traveling to the Far East. He had
an 18-year history of type 2 diabetes
mellitus and chronic sinusitis. Ten
years ago, he started experiencing dry
cough and mild dyspnea on exertion.
The symptoms progressively wors-
ened, presenting with sputum, wheez-
ing, and dyspnea after minor effort. At
the physical examination, he pre-
sented with inspiratory and expiratory
crackles and wheezes diffusely in both
lungs. The chest radiograph and
HRCT are described in table 4. The
pulmonary function test revealed an
obstructive pattern with signs of hyper-
inflation. The blood gas analysis
showed hypoxemia. The search for
HLA Bw54 yielded positive results.
Treatment with low-dose erythromy-
cin has been implemented, with clini-
cal, functional, and radiological im-
provement.
CASE 3
A 70-year-old male, born in Brazil,
Japanese parents, had no history of
traveling to the Far East and a tobacco
use history of 21 pack/year, discontin-
ued 40 years ago. He has experienced
chronic sinusitis since the age of 60.
About 6 years ago, he started experi-
encing mild dyspnea at exertion and
productive cough, which developed in
crisis always with wheezing. He had a
progressive worsening of the symp-
toms, experiencing dyspnea with mini-
mal exertion and constant wheezing.
At physical examination, he presented
with wheezes and rhonchi all over the
lungs. The radiological features are
described in table 4. High resolution
CT is shown in figure 2. The patient
started a low-dose clarithromycin
treatment resulting in clinical and
functional improvement and a signifi-
cant change in the radiograph pattern
after 6 months of treatment.
CASE 4
A 43-year-old black male, born in
Brazil, with no tobacco use history
and chronic sinusitis since the age of
25. Twelve years ago, he started expe-
riencing productive cough and
dyspnea at exertion, sometimes with
wheezing complaints. Treatment for
chronic bronchitis was tried with lit-
tle success. There was a progressive
worsening of the symptoms. At presen-
tation, he had dyspnea with minimal
exertion, and the wheezing was present
more frequently. At physical examina-
tion, he presented with wheezes and
rhonchi all over the lungs. The chest
radiograph and high resolution CT are
described in table 4. After a low-dose
erythromycin treatment, the patient
presented clinical and functional im-
provement.
DISCUSSION
The diagnosis of DPB is based on
clinical, functional, radiological, and
histological criteria. None of these is
a sufficient criterion by itself, since the
isolated finding at any of these crite-
ria is nonspecific and could lead to a
misdiagnosis, such as chronic bronchi-
tis, and therefore to an inadequate
treatment.
The histological pattern described
for the diagnostic criterion9 found in
our 4 patients should not be analyzed
by itself, since other conditions and
diseases, such as cystic fibrosis, bron-
chiectasis and constrictive bronchioli-
tis obliterans, could present the DPB
unit lesion11. Therefore, the clinico-
pathological correlation is the key for
the correct diagnosis of DPB.
Figure 2 - Thoracic high resolution CT patient 3 showing diffuse small airway wall thickness
nodular infiltrate and bronchiolectasis (small arrow).
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Other findings that could help with
the diagnosis of this condition are
chronic paranasal sinusitis2,7 and a per-
sistent elevation of cold agglutinin12.
The symptoms of chronic sinusitis are
present in more than 75% of the pa-
tients and often precede the lower res-
piratory tract symptoms by years7.
Cold agglutinin titer elevation is non-
specific; in DPB it is usually
polyclonal and rises up to 64 times the
normal level. This kind of elevation
can also be seen in infections, such as
those caused by Mycoplasma. How-
ever, in DPB patients, the serological
tests for Mycoplasma are usually nega-
tive. Although useful, a normal cold
agglutinin level does not exclude
DPB, as observed in our patients13.
The sputum cultures usually are
positive and reveal possible infection
or colonization of the airways with
Haemophilus influenza, and less com-
monly with Streptococcus pneumoniae,
Klebsiella pneumoniae, or Staphyloco-
ccus aureus 2,7. In a later stage, these
agents are replaced by Pseudomonas
aeruginosa or other Pseudomonas spe-
cies that could represent a sign of an
advanced stage of the disease13. Two of
our patients presented with Pseu-
domonas at sputum culture. One of
them (case 1), who presented with Pseu-
domonas aeruginosa, had used a large
number of antibiotics before the diag-
nosis and had only clinical improve-
ment, with no significant pulmonary
function or radiological change after
macrolide treatment. This led us to
wonder whether the presence of Pseu-
domonas is a sign of an advanced stage
or is rather a sign of a chronic phase af-
ter a misdiagnosis and excessive use of
antibiotics.
The pulmonary function tests (PFT)
often reveal airflow limitation with re-
duced diffusing capacity and
hypoxemia2, as was observed in our pa-
tients. After at least 6 months of treat-
ment, all of them had an improvement
on the PFT. Two cases showed a marked
increase in the FEV1, in the FEF25-75%,
and in the arterial hemoglobin oxygen
saturation. Case 2 showed also an in-
crease in DLCO (more than 2-fold).
Case 1 showed only a mild improve-
ment, which could be seen as an in-
creased FEF25-75% and DLCO. These
findings reflect the clinical improve-
ment of these patients after the correct
diagnosis and treatment. This improve-
ment was reported as a reduction in the
number of infections, reduction in the
amount of sputum, and a subjective im-
provement in the capacity for physical
exertion that made possible the return
of the patients to their normal activities.
The major HRCT findings included
small rounded areas and branched lin-
ear areas of attenuation, thickened and
dilated walls of bronchioles and bronchi,
and disparities in lung density between
the inner and the outer lung zones as a
result of air trapping. These areas of at-
tenuation corresponded to nodular le-
sions that are found histologically to be
the chronic inflammatory and fibrotic le-
sions in and around the membranous
and respiratory bronchioles and adjacent
alveolar ducts and alveoli9,14. These al-
terations can be seen in the sample pre-
sented as the figure 2.
In an interesting study, a CT score
system was proposed that showed good
correlation with the pulmonary func-
tion test changes after low-dose, long-
term erythromycin treatment 8. We used
this score system as a complementary
evaluation of the post-treatment im-
provement. We found that 3 of our pa-
tients showed a functional improve-
ment that was correlated with the evo-
lution of the HRCT lesions. The other
patient, even with a significant reduc-
tion in the symptoms, had only a mild
functional improvement and presented
no changes in the radiological pattern
evaluated by the CT score.
The findings at lung biopsy and in
the analysis of bronchoalveolar lavage
fluid15-17 do not clarify the real mecha-
nism of treatment with low dose, long-
term macrolide. Many changes have
been reported as a consequence of
erythromycin treatment, such as a de-
crease in the polymorphonuclear
leukocyte-direct migration18, suppres-
sion of hypersecretion19, and a de-
creased percentage of activated T cells
with the expression of HLA-DR in the
peripheral blood of DPB patients20.
We do know that the antibacterial
action of the erythromycin against the
usual isolated organisms from cultures
of sputum of DPB patients (H. influ-
enza and P. aeruginosa) could not be
considered as an important mechanism,
since the concentration of erythromy-
cin in sputum and serum (with the
usual dose of 600 mg daily) are very far
below the minimum inhibitory concen-
tration required for these organisms21.
In spite of this, the use of low dose,
long-term macrolide treatment figures
as the one with large number of studies
showing clinical, functional, and radio-
logical improvement8,16,22-24, as well as
reduction in the mortality rate25.
The etiology and mechanism of
injury in DPB are unknown. The pres-
ence of certain antigens (i.e. HLA
Bw54) and the finding of familial
cases suggest a genetic background to
this disease, which could explain its
increased prevalence in Far East
populations and its rarity in occidental
populations. The HLA Bw54 antigen
is present at a high frequency in the
Japanese population (11% in normal
subjects and 63 % in DPB patients)26.
Only 1 of our patients was positive for
the HLA Bw54 antigen, despite 3 of
them being of Japanese descent. Thus,
we believe that the HLA Bw54 anti-
gen should not be used as a screening
test, but it should be used as another
diagnostic test and as an attempt to
clarify the physiopathologic mecha-
nism of this disease.
There is only one other description
of DPB in a black patient27; and only
few cases in Caucasians3-6. This find-
ing could be a reflection of a different
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mechanism, a different trigger, or a dif-
ficulty in diagnosis by the Western
physicians. Whether other alleles
could play a role in these populations
is yet to be studied28.
The opinions regarding associa-
tion of DPB with environmental factors
are changing. Initially the reports out-
side the Far East were interpreted to
suggest that the travel history should
be a major factor for the diagnosis of
DPB5. However, other cases outside the
Far East and without travel history in
the Far East have been reported 3,4,6,
and this was also observed in our pa-
tients 2, 3, and 4.
The finding of an association be-
tween DPB and rheumatoid arthritis29,30
or even the recurrence of DPB after bi-
lateral lung transplantation27 suggests
that DPB could be part of a systemic
disease. But the physiopathologic
mechanism that could explain this kind
of behavior has not been clarified yet.
Until now, the final presentation of
DPB was thought to be a result of in-
fluence of each one of the factors men-
tioned above: genetic, environmental,
infectious, and systemic immune re-
sponse with an unknown trigger.
We believe that, in part, the low
prevalence of the DPB in the Occidental
populations could also be a result of the
lack of knowledge about this condition,
leading to misdiagnosis. HRCT can be
used as an important method for diag-
nosis of suspicious cases and treatment
follow-up for DPB patients. Its charac-
teristic, but not diagnostic, pattern
should be better known by Occidental
pulmonary physicians as a differential
diagnosis among the sinopulmonary
syndromes.
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ticada? Estudo de quatro casos no
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S. Paulo 57(4):167-174, 2002.
INTRODUÇÃO: A Panbronquiolite
Difusa é uma entidade clínico-patoló-
gica caracterizada pela inflamação crô-
nica dos bronquíolos respiratórios e
que, clinicamente, apresenta-se como
diagnóstico diferencial das síndromes
sino-pulmonares.
MÉTODOS E RESULTADOS:
Apresentamos 4 casos (um negro, dois
descendentes de japoneses e um japo-
nês), que moram no Brasil, nos quais
a suspeita diagnóstica se baseou nos
aspectos clínicos e radiológicos e foi
confirmada através da biópsia
transbrônquica. As principais caracte-
rísticas clínicas eram sinusite crônica,
tosse produtiva, além da presença de
roncos e sibilos. Os testes de função
pulmonar evidenciaram um padrão
obstrutivo. A tomografia de tórax de
alta resolução demonstrou um padrão
nodular difuso, além de ectasia e
espessamento das paredes das vias aé-
reas. O exame histológico evidenciou
acúmulo intersticial de macrófagos
xantomatosos e infiltração de
linfócitos na região dos bronquíolos
respiratórios, sendo que 2 de nossos
casos ainda apresentaram hiperplasia
de tecido linfocitário associado aos
brônquios. Investigamos a presença do
HLA Bw54 nos quatro casos, sendo
apenas um positivo. Após o diagnós-
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tico, instituiu-se o tratamento com
macrolídeos em dose baixa, tendo
como resultado melhora clínica e fun-
cional. Um escore que avalia a exten-
são do padrão nodular, a ectasia e o
espessamento das vias aéreas e ainda
o grau de impactação mucóide visí-
veis à tomografia foi utilizado pré e pós
tratamento evidenciando uma melho-
ra compatível com a observada à fun-
ção pulmonar.
CONCLUSÃO: Concluímos que a
Panbronquiolite Difusa é uma doença
sistêmica, não exclusiva da população
oriental, cujas características clínicas
e radiológicas devem ser melhor co-
nhecidas pelos médicos ocidentais.
DESCRITORES: Panbronquiolite
Difusa. Bronquiolite. Síndrome Sino-
Pulmonar. Doença Intersticial Pul-
monar. Bronquiolectasia.
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